ClinicalTrials.gg
CompletedNCT00102440FACTUpdated Feb 2, 2012Results posted

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout

A Phase 3 interventional study of Febuxostat and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-02-02.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
5th of 29
760 · median 109
Started
2002
the only one that year
Phase 3
10 of 29
none open now
Registered
1st of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 5th largest by enrollment, is the only one that started in 2002, is one of 10 in phase 3, and was the 1st registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout.

Read the detailed description

This was a randomized, controlled, double-blind study of 52 weeks duration. Subjects receiving prior urate-lowering therapy underwent a 2-week washout period prior to randomization. Subjects were then randomized to one of three treatment groups: febuxostat 80 milligram (mg), febuxostat 120 mg, or allopurinol 300 mg. Naproxen (250 mg twice daily) or colchicine (0.6 mg once daily) was provided for prophylaxis of acute gout flares during the washout period and the first 8 weeks of double-blind treatment.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • uric Acid
  • xanthine oxidase
  • tophi
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meeting the preliminary criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout.
  • Serum uric acid ≥ 8.0 milligrams per deciliter (mg/dL) at Baseline

Exclusion criteria

Exclusion Criteria:

  • Serum creatinine >1.5 mg/dL
  • Calculated of \<50 milliliters per minutes (mL/min)
  • Pregnancy or lactation;
  • Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (>325 mg) or other salicylates;
  • (BMI) >50 kilogram per meter²(kg/m²);
  • A history of xanthinuria, active liver disease, or hepatic dysfunction;
  • A history of alcohol abuse or intake of 14 or more alcohol-containing drinks/week.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
760 participants (actual)

Study arms

  • Experimental
    Febuxostat 80 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 120 mg QD

    Drug: Febuxostat

  • Active comparator
    Allopurinol 300 mg QD

    Drug: Allopurinol

Interventions

  • Febuxostat 80 mg, orally, once daily for up to 52 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 120 mg, orally, once daily for up to 52 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)

    Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.

    Time frame: Last 3 Visits (up to 52 weeks)

Secondary outcomes

  1. Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit

    Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.

    Time frame: Week 28

  2. Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit

    Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 52 visit was summarized.

    Time frame: Week 52

  3. Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit

    The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.

    Time frame: Final Visit (up to 52 weeks)

  4. Percent Change From Baseline in Serum Urate Levels at Week 28.

    Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(week 28 - baseline levels/baseline)\]\*100 and summarized.

    Time frame: Baseline and Week 28

  5. Percent Change From Baseline in Serum Urate Levels at Week 52.

    Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as \[(week 52 - baseline levels/baseline)\]\*100 and summarized.

    Time frame: Baseline and Week 52

  6. Percent Change From Baseline in Serum Urate Levels at Final Visit

    The percent change in serum urate from baseline to the Final visit was calculated as \[(Final Visit - baseline levels/baseline)\]\*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.

    Time frame: Baseline and Final Visit (up to 52 weeks)

  7. Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

    The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.

    Time frame: Baseline and Week 28

  8. Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

    The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 52 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.

    Time frame: Baseline and Week 52

  9. Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

    Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.

    Time frame: Baseline and Final Visit (up to 52 weeks)

  10. Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.

    The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.

    Time frame: Baseline and Week 28

  11. Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.

    The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.

    Time frame: Baseline and Week 52

  12. Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.

    Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.

    Time frame: Baseline and Final Visit (up to 52 weeks)

  13. Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.

    The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.

    Time frame: Weeks 8 through 52

07

Results

Posted Jul 16, 2009

Participant flow

Subjects were enrolled at 112 investigative sites, 106 in the United States and 6 in Canada, from 11 July 2002 to 20 February 2004.

Participant flow — Overall Study
MilestoneFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Started256251253
Completed168153187
Not completed889866
Withdrew: Lost to follow-up251821
Withdrew: Adverse event16238
Withdrew: Gout flare10289
Withdrew: Personal reason(s)191313
Withdrew: Other111414
Withdrew: Protocol violation721

Outcome measures

PrimaryPercentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)

Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.

Time frame:
Last 3 Visits (up to 52 weeks)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percentage of Subjects With the Last 3 Serum Urate Levels <6.0 Milligrams Per Deciliter (mg/dL)536221
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Difference in percentage: 32 · 97.5% CI 23.1 to 41.3
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Difference in percentage: 41 · 97.5% CI 31.5 to 49.5
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Fisher Exact · p = 0.072 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit

Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 28 visit was summarized.

Time frame:
Week 28
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 28 Visit728242
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Fisher Exact · p = 0.031 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit

Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was \<6.0 mg/dL at the Week 52 visit was summarized.

Time frame:
Week 52
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percentage of Subjects With Serum Urate <6.0 mg/dL at Week 52 Visit818239
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Fisher Exact · p = 0.883 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit

The percentage of subjects whose serum urate was \<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.

Time frame:
Final Visit (up to 52 weeks)
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit
Percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percentage of Subjects With Serum Urate <6.0 mg/dL at Final Visit748036
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = <0.001 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Fisher Exact · p = 0.164 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Serum Urate Levels at Week 28.

Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as \[(week 28 - baseline levels/baseline)\]\*100 and summarized.

Time frame:
Baseline and Week 28
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in Serum Urate Levels at Week 28.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Serum Urate Levels at Week 28.-46.3 ± 15.76-53.5 ± 18.20-34.8 ± 12.92
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Serum Urate Levels at Week 52.

Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as \[(week 52 - baseline levels/baseline)\]\*100 and summarized.

Time frame:
Baseline and Week 52
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in Serum Urate Levels at Week 52.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Serum Urate Levels at Week 52.-47.7 ± 17.50-53.0 ± 19.31-34.8 ± 13.56
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · ANOVA · p = 0.006 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Serum Urate Levels at Final Visit

The percent change in serum urate from baseline to the Final visit was calculated as \[(Final Visit - baseline levels/baseline)\]\*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.

Time frame:
Baseline and Final Visit (up to 52 weeks)
Reported as:
Mean · percent change from baseline
Percent Change From Baseline in Serum Urate Levels at Final Visit
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Serum Urate Levels at Final Visit-44.7 ± 19.10-51.5 ± 19.91-33.0 ± 15.33
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · ANOVA · p = <0.001 (P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 28 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.

Time frame:
Baseline and Week 28
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.-29.5 (-66.0 to 4.1)-49.5 (-80.0 to -34.9)-28.6 (-54.9 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = >0.999 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.011 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.024 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

The percent change from baseline in primary tophus size as determined by physical measurement was calculated as \[(Week 52 - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.

Time frame:
Baseline and Week 52
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.-83.4 (-100 to -15.6)-65.5 (-85.5 to -38.9)-49.7 (-96.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.083 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.164 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.619 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.

Percent change in primary tophus size was calculated as \[(Final Visit - baseline sizes)/baseline\]\*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.

Time frame:
Baseline and Final Visit (up to 52 weeks)
Reported as:
Median · percent change from baseline
Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.
percent change from baselineFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.-51.7 (-100 to -8.3)-43.8 (-83.0 to 0.0)-39.6 (-65.0 to 1.5)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.080 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.372 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.246 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryChange From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.

The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.

Time frame:
Baseline and Week 28
Reported as:
Median · number of tophi
Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.
number of tophiFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.0.0 (0.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (0.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.674 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.320 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.411 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryChange From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.

The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.

Time frame:
Baseline and Week 52
Reported as:
Median · number of tophi
Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.
number of tophiFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.0.0 (-1.0 to 0.0)-1.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.507 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.188 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.362 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryChange From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.

Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.

Time frame:
Baseline and Final Visit (up to 52 weeks)
Reported as:
Median · number of tophi
Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.
number of tophiFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)0.0 (-1.0 to 0.0)
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.657 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Wilcoxon (Mann-Whitney) · p = 0.444 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Wilcoxon (Mann-Whitney) · p = 0.719 (P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.)
SecondaryPercentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.

The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.

Time frame:
Weeks 8 through 52
Reported as:
Number · percentage of subjects
Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.
percentage of subjectsFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.647064
Statistical analysis
  • Febuxostat 80 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = >0.999 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 120 mg QD vs Allopurinol 300 mg QD · Fisher Exact · p = 0.229 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)
  • Febuxostat 80 mg QD vs Febuxostat 120 mg QD · Fisher Exact · p = 0.266 (Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 80 mg QD—10/256 (3.9%)164/256 (64.1%)
Febuxostat 120 mg QD—19/251 (7.6%)145/251 (57.8%)
Allopurinol 300 mg QD—18/253 (7.1%)167/253 (66%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Coronary Artery Disorders NECCardiac disorders0/2560/2514/253
Heart Failures NECCardiac disorders3/2561/2510/253
Ischaemic Coronary Artery Disorders NECCardiac disorders3/2562/2512/253
Ventricular Arrhythmias and Cardiac ArrestCardiac disorders0/2562/2511/253
Abdominal and Gastrointestinal InfectionsInfections and infestations0/2561/2512/253
Renal Failure and ImpairmentRenal and urinary disorders2/2560/2510/253
Supraventricular ArrhythmiasCardiac disorders1/2561/2510/253
Acute and Chronic PancreatitisGastrointestinal disorders0/2561/2510/253
Intestinal HaemorrhagesGastrointestinal disorders0/2561/2510/253
Intestinal Ulcers and Perforation NECGastrointestinal disorders0/2561/2510/253
Most frequent other events
Showing 10 of 15
Most frequent other events
EventFebuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QD
Upper Respiratory Tract InfectionsInfections and infestations77/25653/25172/253
Joint Related Signs and SymptomsMusculoskeletal and connective tissue disorders39/25632/25137/253
Musculoskeletal and Connective Tissue Signs and Symptoms NECMusculoskeletal and connective tissue disorders35/25638/25137/253
Diarrhoea (Excl Infective)Gastrointestinal disorders27/25625/25116/253
Headache NECNervous system disorders23/25623/25122/253
Nausea and Vomiting SymptomsGastrointestinal disorders19/25613/2518/253
Oedema NECGeneral disorders18/2568/2518/253
Upper Respiratory Tract Signs and SymptomsRespiratory, thoracic and mediastinal disorders13/25610/25117/253
Neurological Signs and Symptoms NECNervous system disorders17/2569/2517/253
Liver Function AnalysesInvestigations13/25616/25112/253

Baseline characteristics

Age, Customized
Age, Customized(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
<45 years757184230
45 years to <65 years140133125398
≥65 years414744132
Age Continuous
Age Continuous(years)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
Mean51.8 ± 11.6952.0 ± 12.1251.6 ± 12.6351.8 ± 12.13
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
Female1381031
Male243243243729
Body Mass Index
Body Mass Index(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
<18.5 kilogram per meter² (kg/m²)0000
18.5 kg/m² to <25 kg/m²1512734
25 kg/m² to <30 kg/m²758789251
≥30 kg/m²166152154472
missing0033
Calculated Creatinine Clearance
Calculated Creatinine Clearance(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
<50 milliliters per minute (mL/min)1381334
50 mL/min to <80 mL/min779068235
80 mL/min to <120 mL/min138130140408
≥120 mL/min28232980
missing0033
Presence of Primary Palpable Tophus
Presence of Primary Palpable Tophus(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
Yes525346151
No, but other tophi present1236
No and no other tophi present203196204603
Race/Ethnicity
Race/Ethnicity(subjects)Febuxostat 80 mg QDFebuxostat 120 mg QDAllopurinol 300 mg QDTotal
White193199195587
Black or African American24201862
Hispanic22171958
Asian109625
Other761528
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. PubMed 16339094 ↗
  • Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032. PubMed 18600509 ↗
  • Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008. PubMed 21353107 ↗
  • Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680. PubMed 22052584 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of Feb 2004 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2005
First posted
Jan 31, 2005
Start
Jul 2002
Primary completionActual
Feb 2004
CompletionActual
Feb 2004
Results first posted
Jul 16, 2009
Last update
Feb 2, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00102440
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jan 31, 2005
Start date
Jul 2002
Primary completion
Feb 2004
Completion
Feb 2004
Results posted
Jul 16, 2009
Last update
Feb 2, 2012

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion